REPLIMUNE GROUP, INC. (REPL) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $84.00K; Additional Paid in CapitalUSD $1.43B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.98M; Retained Earnings (Accumulated Deficit)USD $-1.33B.
- 2026-03-31: Common Stock, Value, IssuedUSD $82.00K; Additional Paid in CapitalUSD $1.42B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.40M; Retained Earnings (Accumulated Deficit)USD $-1.26B.
- 2025-12-31: Common Stock, Value, IssuedUSD $79.00K; Additional Paid in CapitalUSD $1.39B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.56M; Retained Earnings (Accumulated Deficit)USD $-1.19B.
- 2025-09-30: Common Stock, Value, IssuedUSD $78.00K; Additional Paid in CapitalUSD $1.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.12M; Retained Earnings (Accumulated Deficit)USD $-1.12B.
REPLIMUNE GROUP, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $84.00K | $1.43B | $5.98M | $-1.33B | $105.64M | 3 month · $7.67M | (m) | (m) | (m) |
| 2026-03-31 | $82.00K | $1.42B | $5.40M | $-1.26B | $166.16M | 12 month · $32.27M | (m) | (m) | (m) |
| 2025-12-31 | $79.00K | $1.39B | $5.56M | $-1.19B | $210.54M | 3 month · $7.05M | (m) | (m) | (m) |
| 2025-09-30 | $78.00K | $1.38B | $5.12M | $-1.12B | $263.34M | 3 month · $8.34M | (m) | (m) | (m) |
| 2025-06-30 | $78.00K | $1.37B | $4.24M | $-1.04B | $336.71M | 3 month · $8.76M | (m) | (m) | (m) |
| 2025-03-31 | $77.00K | $1.36B | $5.45M | $-948.58M | $415.84M | 12 month · $35.04M | (m) | (m) | (m) |
| 2024-12-31 | $77.00K | $1.35B | $6.16M | $-874.45M | $482.37M | 3 month · $8.64M | (m) | (m) | (m) |
| 2024-09-30 | $68.00K | $1.19B | $3.63M | $-808.11M | $381.46M | 3 month · $8.65M | (m) | (m) | (m) |
| 2024-06-30 | $68.00K | $1.18B | $4.32M | $-755.05M | $426.45M | 3 month · $9.47M | (m) | (m) | (m) |
| 2024-03-31 | $61.00K | $1.07B | $4.86M | $-701.28M | $374.51M | 12 month · $34.12M | (m) | (m) | (m) |
| 2023-12-31 | $61.00K | $1.06B | $4.73M | $-646.21M | $421.54M | 3 month · $8.24M | (m) | (m) | (m) |
| 2023-09-30 | $59.00K | $1.05B | $5.49M | $-595.09M | $465.17M | 3 month · $9.11M | (m) | (m) | (m) |
| 2023-06-30 | $57.00K | $1.05B | $3.97M | $-535.04M | $514.03M | 3 month · $8.85M | (m) | (m) | (m) |
| 2023-03-31 | $57.00K | $1.03B | $5.73M | $-485.49M | $555.29M | 12 month · $28.13M | (m) | 12 month · $300.00K | (m) |
| 2022-12-31 | $57.00K | $1.03B | $3.74M | $-436.25M | $595.35M | 3 month · $7.02M | (m) | 3 month · $300.00K | (m) |
| 2022-09-30 | $50.00K | $777.65M | $2.93M | $-396.56M | $384.07M | 3 month · $6.99M | (m) | 3 month · $300.00K 6 month · $300.00K | (m) |
| 2022-06-30 | $49.00K | $763.15M | $520.00K | $-353.46M | $410.26M | 3 month · $7.19M | (m) | (m) | (m) |
| 2022-03-31 | $47.00K | $723.36M | $-973.00K | $-311.20M | $411.23M | 12 month · $24.25M | (m) | (m) | (m) |
| 2021-12-31 | $47.00K | $717.15M | $-181.00K | $-279.51M | $437.51M | 3 month · $5.92M | (m) | (m) | (m) |
| 2021-09-30 | $47.00K | $707.19M | $9.00K | $-249.83M | $457.41M | 3 month · $6.31M | (m) | (m) | (m) |
| 2021-06-30 | $47.00K | $699.67M | $-210.00K | $-220.48M | $479.02M | 3 month · $6.25M | (m) | (m) | (m) |
| 2021-03-31 | $47.00K | $692.24M | $-394.00K | $-193.17M | $498.73M | 12 month · $11.79M | (m) | (m) | 12 month · $91.65M |
| 2020-12-31 | $46.00K | $687.93M | $-116.00K | $-171.67M | $516.20M | 3 month · $3.05M | $0.00 | 3 month · $13.78M | 3 month · $58.75M |
| 2020-09-30 | $40.00K | $411.85M | $-611.00K | $-149.89M | $261.39M | 3 month · $2.80M | $0.00 | (m) | (m) |
| 2020-06-30 | $40.00K | $408.75M | $-1.19M | $-129.79M | $277.81M | 3 month · $2.47M | $0.00 | (m) | 3 month · $32.90M |
| 2020-03-31 | $37.00K | $296.96M | $-982.00K | $-112.30M | $183.72M | 12 month · $7.74M | $0.00 | (m) | 12 month · $28.14M |
| 2019-12-31 | $37.00K | $295.08M | $-1.05M | $-96.51M | $197.56M | 3 month · $2.34M | $0.00 | (m) | 3 month · $28.14M |
| 2019-09-30 | $32.00K | $202.36M | $-1.43M | $-80.32M | $120.64M | 3 month · $1.78M | $0.00 | (m) | (m) |
| 2019-06-30 | $32.00K | $200.47M | $-1.17M | $-69.18M | $130.15M | 3 month · $1.81M | $0.00 | (m) | (m) |
| 2019-03-31 | $32.00K | $198.65M | $-1.05M | $-59.77M | $137.86M | 12 month · $2.73M | $0.00 | (m) | 12 month · $7.09M |
| 2018-12-31 | $32.00K | $197.70M | $-1.38M | $-53.11M | $143.24M | 3 month · $880.00K 9 month · $1.82M | $0.00 | (m) | 9 month · $86.36M |
| 2018-09-30 | $32.00K | $196.66M | $-1.22M | $-45.44M | $150.04M | 3 month · $718.00K 6 month · $943.00K | $0.00 | (m) | 3 month · $7.09M 6 month · $7.09M |
| 2018-06-30 | $5.00K | $1.32M | $-1.05M | $-38.98M | $-38.70M | 3 month · $225.00K | (m) | (m) | (m) |
| 2018-03-31 | $5.00K | $1.10M | $-238.00K | $-28.93M | $-28.07M | 12 month · $812.00K | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | $-11.52M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |